NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-AI-21-039 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support consortia to conduct research toward the prevention and cure of HIV. The Consortium for Innovative HIV Vaccine and Cure Research will establish a collaborative and integrated research program built around two areas of scientific focus: identification of the correlates and the mechanism(s) of protection of preventive vaccine(s) and the use of vaccines or other immune modalities in advancing cure research. Preclinical studies in nonhuman primate (NHP) models will be supported to investigate the mechanism(s), by which efficacious AIDS vaccines protect NHPs from initial infection or establishment of systemic infection, and will incorporate vaccines or other immune interventions into cure strategies in SIV or SHIV-infected NHPs with the objective of eliminating virus reservoirs or establishing elite control of virus replication. Research findings can be applied to improve HIV vaccines and cure strategies and further advancement toward evaluation in human clinical trials.
Notice NOT-OD-21-118 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-049 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-078 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-052 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-051 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-057 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-21-020 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program.
Funding Opportunity RFA-DK-21-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.
Notice NOT-DA-21-053 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-22-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement(FOA) invites grant applications that address priority gaps in our understanding of human milk as a biological system and that expand our understanding of the myriad factors influencing the composition and function of human milk using a systems biology approach.
Notice NOT-MD-21-022 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-028 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-076 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-075 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-074 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-229 from the NIH Guide for Grants and Contracts. Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.
Funding Opportunity RFA-HL-23-005 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Funding Opportunity RFA-HL-23-004 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.
Funding Opportunity PAR-21-224 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).